Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
|Articles|September 2, 2018
- Pharmaceutical Technology-09-02-2018
- Volume 42
- Issue 9
Isolator and Filling Machine for Vials
groninger and SKAN have collaborated to develop Integra, a production line concept that integrates both an isolator and filling machine for vials with a large capacity range.
groninger and SKAN have collaborated to develop Integra, a production line concept that integrates both an isolator and filling machine for vials with a large capacity range.
The product was developed with a focus on processing toxic products. Features include shorter decontamination cycles and simplified cleaning. The integration of the filling machine into the isolator and the integration of the SKANFOG decontamination system allows the line to be cleaned and decontaminated in approximately 30 minutes with accessibility for operating personnel, according to groninger. Increased security and support for format changes enabled by the use of quick response codes gives operators a better overview of position, installation order, and recipe selection.
Different line configurations are available with either standardized open restricted access barrier systems or isolator modules and are capable of a maximum production output of 400 vials per minute, groninger reports.
Articles in this issue
about 8 years ago
Taste-Blocking—An Alternative to Tastemaskingabout 8 years ago
Coating for Tastemaskingabout 8 years ago
Disputes Over SPC Waiversabout 8 years ago
Lightweight Actuator for Aseptic Valvesabout 8 years ago
Triple Shaft Mixer with Discharge Systemabout 8 years ago
Automated Single-Use System for Filtration and Product Dispensingabout 8 years ago
Be a Part of the Solutionabout 8 years ago
Clinical Manufacturing: Clearing Higher HurdlesRelated to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
3
Complying with International Pharmacopoeias
4
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
5